Cytotoxic profile of CD3+CD20+ T cells in progressive multiple sclerosis.
Mult Scler Relat Disord
; 52: 103013, 2021 Jul.
Article
em En
| MEDLINE
| ID: mdl-34030100
ABSTRACT
Recently, it was shown that highly effective anti-CD20 therapies used for MS patients not only deplete CD20+ B cells, but also a small subset of T cells expressing CD20 surface marker (CD3+CD20+ T cells). Here we demonstrated that, in progressive MS patients, CD3+CD20+ T cells share the ability to express cytotoxic factors such as perforin and serine-protease granzyme-B (GzmB), classically associated with CD8+ T cells functionality. Beyond it, cluster analyses show that a set of activation markers and transcriptional factors related with CD8 effector program are also expressed in CD3+CD20+ T cells. Further characterization of surface and functional markers from CD3+CD20+ T subsets may be helpful for development of new therapeutic strategies mainly for progressive MS patients, as well as for assessing pathophysiological effects of highly effective anti-CD20 therapies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Esclerose Múltipla Crônica Progressiva
/
Esclerose Múltipla
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article